Patents by Inventor Roger Paul Hollis

Roger Paul Hollis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF DESIGNING HIGHLY REGULATED LENTIVIRAL VECTORS POSSESING STRICT ENDOGENOUS REGULATION
    Publication number: 20240082427
    Abstract: In various embodiments method are provided for generating expression cassettes and gene therapy vectors comprising those cassettes that recapitulate the spatiotemporal pattern of expression of the endogenous gene. In certain embodiments the methods comprise (i) selecting a target gene; (ii) identifying putative regulatory elements associated with the target gene; (iii) determining if the regulatory element is a key regulatory element and (iv) providing a list of the key regulatory elements identified in step (iii).
    Type: Application
    Filed: January 28, 2022
    Publication date: March 14, 2024
    Applicant: The Regents of the University of California
    Inventors: Donald B. Kohn, Ryan L. Wong, Roger Paul Hollis, Richard A. Morgan, Aaron Ross Cooper
  • LENTIVIRAL VECTORS IN HEMATOPOIETIC STEM CELLS TO TREAT RECOMBINATION-ACTIVATING GENE 1 (RAG1) SEVERE COMBINED IMMUNODEFICIENCY (SCID)
    Publication number: 20220389454
    Abstract: In certain embodiments a lentiviral vector for the treatment of Recombination-Activating Gene 1 Severe Combined Immunodeficiency (RAG1 SCID) is provided. In certain embodiments the vector comprises an expression cassette comprising a nucleic acid construct comprising an effective fragment of the endogenous promoter of the RAG1 gene and a nucleic acid that encodes the RAG1 protein operably linked to the effective fragment of the endogenous promoter of the RAG1 gene.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 8, 2022
    Applicant: The Regents of the University of California
    Inventors: Donald B. Kohn, Ryan L. Wong, Roger Paul Hollis, Richard A. Morgan
  • LENTIVIRAL VECTORS IN HEMATOPOIETIC STEM CELLS TO TREAT WISKOTT-ALDRICH SYNDROME (WAS)
    Publication number: 20220387528
    Abstract: In certain embodiments a lentiviral vector for the treatment of Wiskott-Aldrich Syndrome (WAS) is provided. In certain embodiments the vector comprises an expression cassette comprising a nucleic acid construct comprising an effective fragment of the endogenous promoter of the WAS gene where said promoter has maximum length of 600 bp and contains the sequence of HS1pro, and a nucleic acid that encodes the Wiskott-Aldrich Syndrome protein (WASp) operably linked to the effective fragment of the endogenous promoter of the WAS gene.
    Type: Application
    Filed: November 10, 2020
    Publication date: December 8, 2022
    Applicant: The Regents of the University of California
    Inventors: Donald B. Kohn, Ryan L. Wong, Roger Paul Hollis
  • LENTIVIRAL VECTORS IN HEMATOPOIETIC STEM CELLS TO TREAT X-LINKED CHRONIC GRANULOMATOUS DISEASE
    Publication number: 20220378937
    Abstract: In certain embodiments a lentiviral vector for the treatment of X-linked chronic granulomatous disease (X-CGD) is provided. In certain embodiments the vector comprises an expression cassette comprising a nucleic acid construct comprising a CYBB promoter or effective fragment thereof; and a nucleic acid that encodes gp91phox operably linked to the CYBB promoter or promoter fragment.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 1, 2022
    Applicant: The Regents of the University of California
    Inventors: Donald B. Kohn, Ryan L. Wong, Roger Paul Hollis
  • AUGMENTATIONS TO LENTIVIRAL VECTORS (CCLC-MGATA/ANK-CORE LCR-BETA-AS3-FB) TO INCREASE EXPRESSION
    Publication number: 20220170045
    Abstract: In certain embodiments a lentiviral vector having an LCR comprising HS1 ENCODE core (EC1) sequence (SEQ ID NO:1), and one or more of an HS2 core sequence (ecHS2), an HS3 core sequence (ecHS3), an HS4 core sequence (ecHS4), a full length HS2, a full length HS3, and/or a full length HS4 sequence is provided. In certain embodiments the vector comprises a modified ?AS3-globin transgene, where transgene comprises a codon optimized exon 1, and/or a codon optimized exon 2, and/or a codon optimized exon 3.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 2, 2022
    Applicant: The Regents of the University of California
    Inventors: Donald B. Kohn, Richard A. Morgan, Roger Paul Hollis
  • OPTIMIZED LENTIVIRAL VECTOR COMPROMISING MINIMAL ENHANCER ELEMENTS FOR STEM CELL GENE THERAPY OF HEMOGLOBINOPATHIES
    Publication number: 20220136007
    Abstract: In certain embodiments a lentiviral vector having optimized reduced size LCR with improved enhancer activity is provided. In certain embodiments direct treatment of a subject by direct introduction of the vector(s) described herein is contemplated. The lentiviral compositions may be formulated for delivery by any available route including, but not limited to parenteral (e.g., intravenous), intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, rectal, and vaginal.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 5, 2022
    Inventors: Donald B. Kohn, Roger Paul Hollis, Richard A. Morgan, Aaron Ross Cooper
  • LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNE DEFICIENCIES AND AUTOIMMUNE DISEASES
    Publication number: 20200347404
    Abstract: In various embodiments, lentiviral vectors expressing FoxP3 using the endogenous gene elements to regulate physiologic gene expression of FoxP3 are provided herein as well as uses of such vectors.
    Type: Application
    Filed: August 22, 2018
    Publication date: November 5, 2020
    Inventors: Donald B. Kohn, Maria Grazia Roncarolo, Roger Paul Hollis, Katelyn E. Masiuk, Rosa Bacchetta
  • Biosensor
    Patent number: 6406856
    Abstract: The present invention relates to a method for evaluating biological effects in a substance which method comprises sampling the substance, subjecting the sample to an assay in the presence of a biosensor engineered with a gene which expresses a light emitting protein and noting the light output; characterized in that the biosensor is eukaryotic and the substance is assayable over any pH between pH1 and pH12. Such a eukaryotic sensor may be derived from Saccharomyces cerevisiae and is useful in assaying potable waters.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: June 18, 2002
    Assignee: Aberdeen University
    Inventors: Lesley Anne Glover, Roger Paul Hollis, Kenneth Stuart Killham